Enzyvant Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Enzyvant Therapeutics, Inc.
The company presented positive data from a Phase III pivotal trial during the American Burn Association virtual annual meeting.
Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.
Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.
- Other Names / Subsidiaries
- Enzyvant Sciences, Ltd.